We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Autophagy and Tau Protein.
- Authors
Hamano, Tadanori; Enomoto, Soichi; Shirafuji, Norimichi; Ikawa, Masamichi; Yamamura, Osamu; Yen, Shu-Hui; Nakamoto, Yasunari
- Abstract
Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzheimer's disease (AD). In swollen axons, many autophagic vacuoles are observed around SP in the AD brain. This suggests that autophagy function is disturbed in AD. We used a neuronal cellular model of tauopathy (M1C cells), which harbors wild type tau (4R0N), to assess the effects of the lysosomotrophic agent NH4Cl, and autophagy inhibitors chloroquine and 3 methyladenine (3MA). It was found that chloroquine, NH4Cl and 3MA markedly increased tau accumulation. Thus, autophagy lysosomal system disturbances disturbed the degradation mechanisms of tau protein. Other studies also revealed that tau protein, including aggregated tau, is degraded via the autophagy lysosome system. Phosphorylated and C terminal truncated tau were also reported to disturb autophagy function. As a therapeutic strategy, autophagy upregulation was suggested. Thus far, as autophagy modulators, rapamycin, mTOCR1 inhibitor and its analogues, lithium, metformin, clonidine, curcumin, nicotinamide, bexaroten, and torehalose have been proposed. As a therapeutic strategy, autophagic modulation may be the next target of AD therapeutics.
- Subjects
TAU proteins; NEUROFIBRILLARY tangles; AUTOPHAGY; AMYLOID plaque; ALZHEIMER'S disease
- Publication
International Journal of Molecular Sciences, 2021, Vol 22, Issue 14, p7475
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms22147475